% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hoeltgen:285052,
      author       = {L. Hoeltgen and T. Tessonnier$^*$ and E. Meixner and P.
                      Hoegen$^*$ and J.-Y. Kim and M. Deng and K. Seidensaal and
                      T. Held and K. Herfarth and J. Debus$^*$ and S. Harrabi},
      title        = {{P}roton {T}herapy for {A}dvanced {J}uvenile
                      {N}asopharyngeal {A}ngiofibroma.},
      journal      = {Cancers},
      volume       = {15},
      number       = {20},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-02195},
      pages        = {5022},
      year         = {2023},
      note         = {#EA:E050#},
      abstract     = {To provide the first report on proton radiotherapy (PRT) in
                      the management of advanced nasopharyngeal angiofibroma (JNA)
                      and evaluate potential benefits compared to conformal photon
                      therapy (XRT).We retrospectively reviewed 10 consecutive
                      patients undergoing PRT for advanced JNA in a definitive or
                      postoperative setting with a relative biological
                      effectiveness weighted dose of 45 Gy in 25 fractions between
                      2012 and 2022 at the Heidelberg Ion Beam Therapy Center.
                      Furthermore, dosimetric comparisons and risk estimations for
                      short- and long-term radiation-induced complications between
                      PRT plans and helical XRT plans were conducted.PRT was well
                      tolerated, with only low-grade acute toxicities (CTCAE I-II)
                      being reported. The local control rate was $100\%$ after a
                      median follow-up of 27.0 (interquartile range 13.3-58.0)
                      months. PRT resulted in considerable tumor shrinkage,
                      leading to complete remission in five patients and bearing
                      the potential to provide partial or complete symptom relief.
                      Favorable dosimetric outcomes in critical brain
                      substructures by the use of PRT translated into reduced
                      estimated risks for neurocognitive impairment and
                      radiation-induced CNS malignancies compared to XRT.PRT is an
                      effective treatment option for advanced JNA with minimal
                      acute morbidity and the potential for reduced
                      radiation-induced long-term complications.},
      keywords     = {NTCP (Other) / juvenile nasopharyngea angiofibroma (JNA)
                      (Other) / late effects (Other) / neurocognitive impairment
                      (Other) / pediatry (Other) / proton radiotherapy (Other) /
                      radiotherapy (Other) / secondary cancers (Other)},
      cin          = {E050 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37894389},
      pmc          = {pmc:PMC10605854},
      doi          = {10.3390/cancers15205022},
      url          = {https://inrepo02.dkfz.de/record/285052},
}